CUPRIMINE Drug Patent Profile

Which patents cover Cuprimine, and when can generic versions of Cuprimine launch?

Cuprimine is a drug marketed by Valeant Pharms Intl and is included in one NDA.

The generic ingredient in CUPRIMINE is penicillamine. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the penicillamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cuprimine

A generic version of CUPRIMINE was approved as penicillamine by WATSON LABS INC on June 24^th, 2019.

Summary for CUPRIMINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CUPRIMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms Intl	CUPRIMINE	penicillamine	CAPSULE;ORAL	019853-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharms Intl	CUPRIMINE	penicillamine	CAPSULE;ORAL	019853-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

CUPRIMINE (PENICILLAMINE) PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS

Last updated: February 19, 2026

Executive Summary

Cuprimine (penicillamine) is an orally administered chelating agent with established therapeutic applications in Wilson disease, cystinuria, and rheumatoid arthritis. Its primary active pharmaceutical ingredient, D-penicillamine, is a well-characterized molecule with a long history of clinical use and established efficacy. The intellectual property surrounding Cuprimine is largely characterized by expired foundational patents, with subsequent patent activity focused on formulation improvements, specific indications, and manufacturing processes. Current market exclusivity relies on the absence of direct bioequivalent generic competitors for certain formulations and the established brand recognition of Cuprimine. Investment opportunities hinge on the potential for life cycle management, new indication development, or strategic acquisition within the context of existing market dynamics and generic competition.

Is Cuprimine's Original Patent Protection Expired?

The foundational patents protecting D-penicillamine, the active pharmaceutical ingredient in Cuprimine, have long since expired. These early patents covered the compound itself and its initial therapeutic uses. For instance, U.S. Patent 2,737,499, covering penicillamine and its use in treating heavy metal poisoning, was granted in 1956 and expired decades ago. Similarly, patents related to its use in rheumatoid arthritis and cystinuria have also lapsed. This means the core molecule is in the public domain, allowing for generic manufacturing.

What Are Cuprimine's Approved Indications?

Cuprimine is approved for the treatment of several specific conditions:

• Wilson Disease: A rare genetic disorder characterized by the excessive accumulation of copper in organs, primarily the liver, brain, and eyes. Penicillamine promotes the excretion of copper by forming soluble complexes with it.
• Cystinuria: A genetic disorder that causes the formation of cysteine kidney stones. Penicillamine reduces cystine levels in the urine by breaking disulfide bonds in cystine, forming cysteine and penicillamine-cysteine mixed disulfides, which are more soluble.
• Rheumatoid Arthritis: While not a first-line treatment, penicillamine is used as a disease-modifying antirheumatic drug (DMARD) for severe cases of rheumatoid arthritis that have not responded to other treatments. It modulates the immune system to reduce inflammation.

What is the Current Patent Landscape for Cuprimine?

The contemporary patent landscape for Cuprimine is complex, with most activity centered on specific advancements rather than the core molecule. The absence of broad, composition-of-matter patents for D-penicillamine means that generic manufacturers can produce the active ingredient. However, patents continue to be filed and granted for:

• Formulation Improvements: New delivery systems, controlled-release formulations, or combination therapies involving penicillamine. For example, patents might protect specific tablet coatings, excipient combinations, or methods to improve palatability or reduce side effects.
• Specific Manufacturing Processes: Novel or improved methods for synthesizing D-penicillamine or its salts, aiming for higher purity, yield, or cost-efficiency. These process patents can create barriers to entry for competitors if they are difficult to circumvent.
• New Indications or Patient Subgroups: Patents that claim the use of penicillamine for novel therapeutic areas or for specific patient populations exhibiting a particular genetic marker or disease subtype.
• Polymorphs and Salt Forms: Patents can cover specific crystalline forms (polymorphs) or salt forms of penicillamine that may offer improved stability, bioavailability, or manufacturing characteristics.

Table 1: Representative Patent Categories for Penicillamine

Patent Category	Description	Example Focus
Composition of Matter	Claims the active pharmaceutical ingredient itself.	Original patents for D-penicillamine (Expired).
Method of Use	Claims specific therapeutic applications or treatment protocols.	Patents for Wilson Disease, Cystinuria, Rheumatoid Arthritis.
Formulation	Claims specific dosage forms, delivery systems, or combinations.	Extended-release tablets, pediatric formulations, topical creams.
Manufacturing Process	Claims methods for synthesizing or purifying the active pharmaceutical ingredient.	Novel synthesis routes, purification techniques.
Polymorph/Salt Form	Claims specific crystalline forms or salt derivatives of the API.	Stable crystalline forms with enhanced dissolution profiles.
Repurposing/New Indications	Claims the use of the drug for previously unapproved diseases or patient groups.	Use in autoimmune disorders beyond RA, fibrotic diseases.

What Are the Key Investment Considerations for Cuprimine?

Investment in Cuprimine requires a nuanced assessment of its market position, competitive landscape, and potential for future growth. Key considerations include:

• Generic Competition: The absence of patent protection on the core molecule means generic versions of penicillamine are available. This significantly impacts pricing power and market share for branded products. Investors must evaluate the extent and aggressiveness of generic competition for specific formulations and indications.
• Market Size and Growth Potential: The primary indications for Cuprimine, such as Wilson disease and cystinuria, are rare diseases. While this can offer some protection from broad generic erosion due to smaller patient populations, it also limits the overall market size. Rheumatoid arthritis is a larger market, but Cuprimine is generally a second or third-line therapy in this indication, facing competition from newer, more targeted biologics and small molecules.
• Intellectual Property Strategy: While core patents have expired, ongoing patenting activity around formulations, processes, and new indications can create niche market exclusivity or barriers to entry for specific competitors. Investors should scrutinize the strength, scope, and remaining lifespan of these secondary patents.
• Life Cycle Management: Pharmaceutical companies may pursue life cycle management strategies to extend product exclusivity and revenue streams. This can include developing new formulations (e.g., improved absorption, reduced side effects), combination therapies, or seeking approval for new indications. The success of such strategies is critical for sustained investment value.
• Manufacturing and Supply Chain: Reliable and cost-effective manufacturing is paramount. Investors should assess the efficiency of existing manufacturing processes, potential for cost optimization, and any intellectual property protecting these processes. Supply chain robustness is also a factor, especially for drugs treating chronic conditions.
• Regulatory Environment: Compliance with regulatory standards from agencies like the FDA and EMA is essential. Any issues related to drug safety, efficacy, or manufacturing quality can significantly impact investment. The regulatory pathways for new indications or formulation changes must also be considered.
• Competitive Therapies: The development of new and more effective treatments for Wilson disease, cystinuria, and rheumatoid arthritis could erode Cuprimine's market share. Investors must monitor the pipeline of competing drugs and their clinical trial progress. For example, newer chelating agents for Wilson disease or novel treatments for rheumatoid arthritis could pose a significant threat.
• Orphan Drug Status: For indications like Wilson disease and cystinuria, penicillamine might have qualified for orphan drug exclusivity periods, providing market exclusivity for a defined duration after approval for that specific indication. While the compound itself is off-patent, such exclusivity could have protected specific branded formulations for a period.

Is There Active Litigation or Patent Disputes Surrounding Cuprimine?

While the foundational patents for penicillamine are long expired, patent litigation can still arise concerning secondary patents, such as those covering specific formulations, manufacturing processes, or new uses. Disputes typically occur when a generic manufacturer challenges the validity or infringement of a remaining patent, or when a patent holder alleges infringement by a generic product.

Key areas for potential litigation include:

• "Paragraph IV" Challenges: Under the Hatch-Waxman Act in the United States, generic manufacturers can challenge the validity of unexpired patents listed in the Orange Book. If successful, this can pave the way for earlier generic market entry.
• Process Patent Disputes: Litigation can arise over alleged infringement of patents claiming novel and non-obvious methods for manufacturing penicillamine.
• Formulation Patent Disputes: Challenges to patents covering specific pharmaceutical compositions or delivery systems, particularly if a generic company develops a non-infringing alternative.

A thorough due diligence process would involve examining patent litigation databases and legal dockets to identify any ongoing or recently concluded disputes relevant to Cuprimine or its generic equivalents.

What is the Market Size and Competitive Landscape for Cuprimine's Indications?

The market size and competitive landscape for Cuprimine's indications vary significantly:

Wilson Disease

• Prevalence: Wilson disease is considered a rare disease, with an estimated prevalence of 1 in 30,000 to 1 in 40,000 individuals worldwide.
• Market Size: Given its rarity, the direct market for Wilson disease treatments is relatively small. However, the high unmet need and the chronic nature of the disease create a stable, albeit niche, demand.
• Competition: Penicillamine is a first-line treatment option. However, other chelating agents like trientine (e.g., Syprine) and newer therapies, including zinc acetate, are also used. The choice of therapy often depends on patient response, tolerability, and specific disease manifestations. The market is characterized by specialized physicians and patient advocacy groups.

Cystinuria

• Prevalence: Cystinuria is also a rare genetic disorder, with an estimated prevalence ranging from 1 in 7,000 to 1 in 10,000 individuals.
• Market Size: Similar to Wilson disease, the market for cystinuria treatment is limited by the disease's rarity.
• Competition: Penicillamine is a primary medical therapy for reducing cystine levels. Other therapeutic approaches include alpha-mercaptopropionic acid and lifestyle modifications (hydration, diet). Management often involves urologists and nephrologists.

Rheumatoid Arthritis (RA)

• Prevalence: Rheumatoid arthritis is a common autoimmune disease affecting approximately 1% of the global population.
• Market Size: The RA market is substantial and highly competitive, valued in the billions of dollars.
• Competition: Penicillamine is considered a disease-modifying antirheumatic drug (DMARD) and is typically reserved for patients who have not responded adequately to other treatments, often due to its side effect profile. It faces intense competition from:
  • Other Conventional DMARDs: Methotrexate, sulfasalazine, hydroxychloroquine.
  • Biologics: Tumor necrosis factor (TNF) inhibitors (e.g., adalimumab, etanercept), interleukin inhibitors (e.g., tocilizumab), and B-cell depleting agents.
  • Targeted Synthetic DMARDs (tsDMARDs): Janus kinase (JAK) inhibitors (e.g., tofacitinib, baricitinib). The RA market is driven by innovation, with a continuous influx of new therapies offering improved efficacy and safety profiles.

What Are the Potential Growth Levers for Cuprimine?

Despite the challenges posed by generic competition and its established therapeutic profile, several avenues exist for potential growth or value enhancement for Cuprimine:

1. Life Cycle Management through Formulation Innovation:

   • Improved Tolerability: Developing new formulations designed to mitigate the known side effects of penicillamine (e.g., gastrointestinal distress, bone marrow suppression, renal toxicity). This could involve modified-release technologies or novel excipient combinations.
   • Enhanced Bioavailability/Pharmacokinetics: Creating formulations that offer more predictable absorption or sustained drug levels, potentially allowing for lower or less frequent dosing.
   • Pediatric Formulations: Developing palatable and easy-to-administer formulations specifically for pediatric populations, which is crucial for treating rare genetic disorders like Wilson disease and cystinuria in children.
   • Combination Therapies: Exploring synergistic effects by combining penicillamine with other agents for specific indications, potentially offering improved efficacy or enabling reduced doses of individual components.

2. Exploration of New Indications (Repurposing):

   • Fibrotic Diseases: Penicillamine has shown some potential in early research for treating fibrotic conditions, such as scleroderma. Further clinical investigation could lead to new approved uses.
   • Other Autoimmune Disorders: Beyond rheumatoid arthritis, its immunomodulatory properties might be relevant for other autoimmune conditions where inflammation and tissue remodeling are key. Rigorous clinical trials would be necessary.
   • Metal Overload Disorders: Investigating its efficacy in managing other forms of metal accumulation or toxicity beyond Wilson disease.

3. Manufacturing Process Optimization:

   • Cost Reduction: Developing more efficient, higher-yield synthesis routes or purification methods can significantly reduce manufacturing costs, improving profitability, especially in a genericized market.
   • Green Chemistry Initiatives: Implementing environmentally friendly manufacturing processes can align with corporate sustainability goals and potentially reduce operational expenses.
   • Proprietary Manufacturing IP: Obtaining patents for novel and efficient manufacturing processes can create a competitive advantage and deter competitors from easily replicating production.

4. Strategic Partnerships and Licensing:

   • Collaboration for Development: Partnering with academic institutions or smaller biotech firms to explore new indications or novel formulations can share R&D costs and accelerate development.
   • Licensing Opportunities: Licensing out manufacturing technology or specific formulation patents to third parties can create royalty revenue streams.

5. Geographic Market Expansion:

   • While established in many Western markets, there may be opportunities to expand access or gain new approvals in emerging markets where generic penetration might be lower or regulatory pathways are different.

Key Takeaways

Cuprimine's investment profile is defined by its mature status as an off-patent molecule with established therapeutic roles in rare diseases and a niche position in rheumatoid arthritis. Its value proposition is increasingly tied to strategic life cycle management, particularly through formulation innovation and potential indication expansion, rather than inherent compound-based market exclusivity. The competitive landscape is dominated by generic alternatives for its core indications, necessitating a focus on differentiated product offerings or cost-efficient manufacturing. Investment decisions should weigh the stability of demand in rare disease indications against the intense competition and evolving treatment paradigms in larger therapeutic areas like rheumatoid arthritis.

Frequently Asked Questions

1. What is the primary challenge to Cuprimine's profitability? The primary challenge is the widespread availability of generic D-penicillamine due to expired foundational patents, which leads to significant price erosion and limits pricing power for any branded version.

2. Can new patents significantly extend Cuprimine's market exclusivity? New patents, if granted for novel formulations, improved manufacturing processes, or entirely new indications with orphan drug status, can provide limited periods of extended exclusivity or create barriers to entry for specific competitors, but they do not restore compound-level protection.

3. What are the risks associated with investing in a drug with established but limited indications like Cuprimine? Risks include the market size being constrained by the rarity of indications, vulnerability to new and more effective competing therapies, and the potential for regulatory scrutiny on long-term safety profiles.

4. How does the manufacturing process IP impact the investment case? Patents on efficient or novel manufacturing processes can lower production costs, enhance product purity, or create a competitive advantage by making it harder for generics to replicate the product economically, thereby supporting profitability even in a post-patent era.

5. What is the outlook for Cuprimine in the rheumatoid arthritis market? The outlook in rheumatoid arthritis is limited. Cuprimine is a third- or fourth-line therapy facing intense competition from newer biologics and targeted synthetic DMARDs with superior efficacy and safety profiles, making it unlikely to regain significant market share in this indication.

Citations

[1] U.S. Patent 2,737,499. (1956). Method of treating heavy metal poisoning. Retrieved from USPTO Patent Database. [2] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website. [3] National Organization for Rare Disorders. (n.d.). Wilson Disease. Retrieved from NORD website. [4] Cystinosis Research Foundation. (n.d.). Cystinuria. Retrieved from CRF website. [5] Centers for Disease Control and Prevention. (2023, November 21). Rheumatoid Arthritis. Retrieved from CDC website.